It has been shown that racial differences exist in the clinical efficacy of cancer patients receiving targeted therapies in different regions, and the efficiency of patients with PD-1/PD-L1 inhibitors may vary depending on geographic location, which will likely be another important reason for the presence of heterogeneity. Here, CD274 is linked to cancer.